Successful treatment of a PNH patient non‐responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan)
Open Access
- 16 December 2019
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 188 (2), 334-337
- https://doi.org/10.1111/bjh.16305
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implicationsSeminars in Hematology, 2018
- Use of the complement inhibitor Coversin to treat HSCT-associated TMABlood Advances, 2017
- Structural basis for therapeutic inhibition of complement C5Nature Structural & Molecular Biology, 2016
- Genetic Variants in C5 and Poor Response to EculizumabNew England Journal of Medicine, 2014
- Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survivalBlood, 2011
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008
- Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaBlood, 2007
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2006
- Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2004